PanOptica, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 101
- Market Cap
- -
Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
Phase 1
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: PAN-90806 Ophthalmic Suspension
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- PanOptica, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03479372
- Locations
- 🇺🇸
Retinal Consultants of Nevada, Las Vegas, Nevada, United States
🇺🇸Duke University, Durham, North Carolina, United States
ðŸ‡ðŸ‡ºUniversity of Debrecen, Debrecen, Hungary
Study of Topical Ocular PAN-90806 in PDR
Phase 1
Completed
- Conditions
- Diabetic Retinopathy
- Interventions
- Drug: PAN-90806 Ophthalmic Solution
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- PanOptica, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02475109
- Locations
- 🇺🇸
Valley Retina Institute, McAllen, Texas, United States
Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
Phase 1
Completed
- Conditions
- Age-Related Macular Degeneration (AMD)
- Interventions
- Drug: PAN-90806 Ophthalmic Solution
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- PanOptica, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02022540
© Copyright 2025. All Rights Reserved by MedPath